Sona Nanotech, Inc. · CSE:SONA
Sona Nanotech — Investor Presentation (November 2023)
23 slides from Sona Nanotech's investor presentation, November 2023
Slide 1: A Therapy to Eliminate Certain Tumors Without the Collateral Damage of Chemo, Radiation or Surgery
A Therapy to Eliminate Certain Tumors Without the Collateral Damage of Chemo, Radiation or Surgery November 2023 sonanano.com CSE: SONA | OTCQB: SNANF
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking information under Actual results may differ materially from those set forth in applicable securities law. All information that addresses this presentation due to risks and uncertainties affecting Sona activities or developments tha
Slide 3: Sona Has Engineered the Right 'Gene Pool' to Pursue Its Cancer Therapy
Sona Has Engineered the Right ‘Gene Pool’ to Pursue Its Cancer Therapy Board Mark Lievonen Walter Strapps PhD Neil Fraser Dr. Michael Gross Jim Megann Chairman Director Director Director Director o Led vaccine maker Sanofi- o CEO of Khosla Ventures o Led Medtronic Canada for ~20 o Surgeon and Corpor
Slide 4: Sona Nanotech at a Glance
Sona Nanotech at a Glance BIOCOMPATIBLE GNR GOLD NANOROD TECHNOLOGY Sona’s Proprietary Technology Sona’s Gold Nanorod Advantages • Patented*, biocompatible, Uniquely Biocompatible: proprietary gold nanorod Sona surfactant uses no toxic CTAB ** • Equally as effective at heat transfer as CTAB-based GN
Slide 5: Therapies
01 BIOCOMPATIBLE GNR GOLD NANOROD TECHNOLOGY Sona Gold Nanorod ("GNR") Technology Uniquely biocompatible Unlocking of in-vivo medical applications potential GNR-Based by developing ‘Targeted Hyperthermia Therapy’ Therapies sonanano.com 5
Slide 6: Treatment for Rectal Cancer is Often Limited to Risky Surgery, Resulting in Side Effects
Treatment for Rectal Cancer is Often Limited to Risky Surgery, Resulting in Side Effects Leading to Poor Quality of Life Total Mesorectal Excision Wait and Short course Long course Watch chemo chemo • Lack of structural complexity • Lack of structural complexity If no success: (“Total mesorectal exc
Slide 7: Sona is Developing a Therapy to Shrink Tumors Without Surgery, Chemo or Radiation
Sona is Developing a Therapy to Shrink Tumors Without Surgery, Chemo or Radiation with Positive Results to Date Day 0 Day 19 Day 59 Immediately after Tumor mass gone “Durable cure” treatment, (same mouse in all images) large multi-lobed tumor Popp, M.K., Oubou, I., Shepherd, C., Nager, Z., Anderson,
Slide 8: Targeted Hyperthermia Therapy Will Use Current Technology to Apply Infrared Light to Nanorod-Saturated Tumors
‘Targeted Hyperthermia Therapy (“THT”) Will Use Current Technology to Apply Infrared (“IR”) Light to Nanorod-Saturated Tumors A Two-step Therapy Step 1. Step 2. Inject Biocompatible Shine IR Light Tuned Gold Nanorods to 850nm on tumor Nanoparticles shown in a red Sona’s light device applied to tumor
Slide 9: THT's Hyperthermia Approach is Designed to Kill Cancer Cells While Not Harming Healthy Tissue
THT’s ‘Hyperthermia’ Approach is Designed to Kill Cancer Cells While Not Harming Healthy Tissue Steak As An Analogy For Human Tissue Current Approach: Sona’s THT Approach: “ABLATION” “HYPERTHERMIA” (> 55°C) (~44°C) Medium-well Blue Rare Ablation ‘cooks’ healthy tissue Hyperthermia leaves healthy tis
Slide 10: Gold Nanorods are Highly Efficient at Converting Harmless IR Light Energy into Heat
Gold Nanorods are Highly Efficient at Converting Harmless IR Light Energy into Heat Which Can Be Used to Kill Cancer Cells 120 Simulated Tumor Heating Using IR Light 110 Simulated tumor – WITH nanorods embedded 100 Temp (°F) 90 Simulated tumor – NO nanorods embedded 80 70 An IR Light Shining on a 60
Slide 11: Plus, 'Hyperthermia' Brings Multiple, Incremental Physiological Benefits
Plus, ‘Hyperthermia’ Brings Multiple, Incremental Physiological Benefits Shrinks tumors Causes cancer cell death Kills cancer stem cells Targeted Hyperthermia Often drug-resistant Therapeutic Heat 44°C / 111°F Increases tumor perfusion Could enhance drug therapy Stimulates immune system Targets meta
Slide 12: Goal to 'Steal' Market Share From Chemo, Radiation and Resection Surgeries for Rectal Cancer
Goal to ‘Steal’ Market Share From Chemo, Radiation and Resection Surgeries for Rectal Cancer Stage 1 Stage 2 Stage 3 Stage 4 Cancer Stage Local Regional Lymph Node Metastatic Characteristics • Lack of structural complexity Watch and Current Standard of Care CRT/Resection CRT/Resection CRT/Resection
Slide 13: The Risks of the Commercialization of THT May Be More Operational than Science Related
The Risks of the Commercialization of THT May Be More Operational than Science Related Previously Done/Approved: Sona To Do: - Using heat to kill cancer cells 1. Deliver infrared light device that can monitor temperature in real time - Photothermal treatment using infrared light devices 2. Preclinic
Slide 14: Compelling Prospective Market and Potential to Save Thousands of Lives Annually
Compelling Prospective Market and Potential to Save Thousands of Lives Annually Cancer Rectal Colon Esophageal Head & Neck Total Cases Reported 46,000 106,000 21,000 67,000 238,000 per • Lack of Year structural complexity Expected to be 40,000 9,000 30,000 106,000 28,000 Treatable by THT Current Dea
Slide 15: Progress Updates: Innovative Efficacy Study Secured With Medical School Laboratory
Progress Updates: Innovative Efficacy Study Secured With Medical School Laboratory Goals: • Evaluate the efficacy of Sona's Targeted Hyperthermia Therapy ("THT") technology in colorectal, breast, and melanoma tumor murine models in mice • Assess ability to combine with immunology to facilitate syste
Slide 16: Diagnostics
02 Lateral Flow Assays (LFA’s) BIOCOMPATIBLE as diagnostic tools are: Can provide rapid GNR • Simple results (e.g. at-home GOLD NANOROD TECHNOLOGY • Fast pregnancy tests) at • Low-cost point-of-care • Rely on nanoparticles How could Sona’s GNRs make a difference? • Multiple test lines per unit GNR-
Slide 17: Sona's Bovine Tuberculosis (bTB) Test Prototype
Sona’s “Bovine TB detection methods are Bovine 17.7m often labor-intensive, and require further confirmatory tests, increasing Tuberculosis Annual bTB testing events in costs and processing times needed for diagnosis. Using a rapid screening (“bTB”) Test UK assay could help minimise that burden and
Slide 18: Near-Term Milestones Anticipated
Near-Term Milestones Anticipated 1. Panel of leading EXCITE International expert advisors from top U.S. institutions and ‘payors’ to provide guidance • To ensure that Sona’s product development is in line with what surgical oncologists are looking for, prior to FDA submission 2. Selection of pre-cli
Slide 19: October 2023 Financing
October 2023 Financing: As of Oct 16, 2023 Market Capitalization Capital Structure Share Price C$0.21 Issued & Outstanding 95.1M Market Cap. C$20M Options 5.5M 52 Week High/Low $0.315/$0.075 Warrants 0.8M Private placement Equity Offering Offering Details: • Private placement of 3,750,000 Units • Un
Slide 20: Thank you
info@sonanano.com Purdy’s Wharf Tower II Suite 2001 – 1969 Upper Water Street Halifax, Nova Scotia, Canada B3J 3R7 +1 902 442 0653 CSE: SONA | OTCQB: SNANF BIOCOMPATIBLE GNR GOLD NANOROD TECHNOLOGY Thank you David Regan david@sonanano.com • Lack of structural complexity +1 902 448 1416 sonanano.com
Slide 21: Appendix
APPENDIX 21
Slide 22: Appendix A Additional Sources
Appendix A Additional Sources in document 1. Mousavi SM, Hashemi SA, Mazraedoost S, Yousefi K, Gholami A, Behbudi G, Ramakrishna S, Omidifar N, Alizadeh A, Chiang WH. Multifunctional Gold Nanorod for Therapeutic Applications and Pharmaceutical Delivery Considering Cellular Metabolic Responses, Oxida
Slide 23: Appendix B Additional Reading
Appendix B Additional Reading Gold Nanorods Traumatic Brain Injury Gold nanorods as contrast agents for biological imaging: optical properties, surface conjugation and photothermal Injury in review, 2020 edition: Spotlight on traumatic brain injuries across the life course - effects Traumatic Brain
Sona Nanotech — Investor Presentation (November 2023) on 6ix